Eye News and Research

Latest Eye News and Research

OXiGENE applies for voluntary delisting from SSE, continues to be listed on NASDAQ

OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has applied for the voluntary delisting of OXiGENE common shares from the Stockholm Stock Exchange (SSE). The company will continue to be listed on the NASDAQ Global Markets exchange.

23 Apr 2010

Genetic tests that may replace biopsies

Genetic tests conducted on blood samples may replace the current biopsies when it comes to checking if immune systems are rejecting new organs of heart transplant patients. The test would be far less invasive and uncomfortable as compared to the biopsies, not to mention more affordable.

23 Apr 2010

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).

22 Apr 2010

Green tea catechins may protect against glaucoma and other common eye diseases: Scientists

Scientists have confirmed that the healthful substances found in green tea - renowned for their powerful antioxidant and disease-fighting properties - do penetrate into tissues of the eye. Their new report, the first documenting how the lens, retina, and other eye tissues absorb these substances, raises the possibility that green tea may protect against glaucoma and other common eye diseases.

22 Apr 2010

Merck to market and distribute MBL's Td vaccine in the U.S.

MassBiologics of the University of Massachusetts Medical School and Merck & Co., Inc. announced today that they have entered into an agreement that provides Merck with exclusive rights to market and distribute MBL's tetanus and diphtheria toxoids adsorbed (Td) vaccine in the United States, with the exception of Massachusetts, where MBL will continue distributing the vaccine.

21 Apr 2010

IP Advocate founder settles long-standing legal battle with UGARF

In a move that positions IP Advocate for its next chapter as a champion of research translation, founder Dr. Renee Kaswan today announced that she has settled her long-standing legal battle with the University of Georgia Research Foundation.

21 Apr 2010

A*STAR's BMRC and SIgN award grants for twelve research projects on infectious diseases and immunology

Twelve research projects on infectious diseases and immunology have been awarded grants by A*STAR's Biomedical Research Council (BMRC) and Singapore Immunology Network (SIgN) this year.

21 Apr 2010

Contrary to previous studies, people with Moebius syndrome lead successful lives

A smile means happiness, a frown sadness, a raised brow surprise. Even when languages and cultures differ, people have this universal form of communication. But Moebius syndrome, a rare congenital condition causing facial paralysis, can rob people of this basic connection, affecting social interaction.

21 Apr 2010

Hearing tests needed for children

The importance of hearing testing isn't widely understood by many parents. Parents may schedule appointments with an opthamologist for an eye exam for their children at regular intervals - but never think to similarly schedule a hearing test with an audiologist.

21 Apr 2010

Effects of UV radiation may increase chance of developing eye problems later in life

While 85 percent of Americans recognize that ultraviolet rays can damage their eyes, only 65 percent wear sunglasses as protection, and even fewer (39 percent) make sure their children wear sunglasses. By comparison, 78 percent make sure their children wear sunscreen when outdoors.

21 Apr 2010

U. S. senators propose retinal scanning may serve as an identity proof

The configuration of retinal blood vessels is unique to each individual and cannot be altered, said Dr. Brian Proctor, an ophthalmologist at Gottlieb Memorial Hospital in Melrose Park, Il.

21 Apr 2010

CryoSTAT cold therapy for hemorrhoids

Revolutionary new CryoSTAT is here to put the fire out when it comes to hemorrhoids by treating them on contact with cold therapy which has a proven track record of providing instant relief with no mess.

20 Apr 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

Exposure to dust after WTC collapse impairs ability to detect odors and sense irritants

Individuals involved in rescue, recovery, demolition, and clean-up after the World Trade Center (WTC) disaster on September 11, 2001, were exposed to a complex mixture of airborne smoke, dust, combustion gases, acid mists, and metal fumes. The impact of this exposure on responders' upper and lower respiratory function has been well documented, but little is known about its impact on their sensitivity to odor and irritants.

19 Apr 2010

Handheld SD-OCT device helps examine vitreoretinal interface in infants with SBS

Ophthalmologists examining infants for possible Shaken Baby Syndrome (SBS) found that a handheld Spectral Domain Optical Coherence Tomography (SD-OCT) device provided high-resolution images of the retina and the vitreoretinal interface in infants with SBS, reports a study in the current issue of Retina, The Journal of Retinal and Vitreous Diseases.

17 Apr 2010

Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment

Santen Pharmaceutical Co., Ltd. and Inspire Pharmaceuticals, Inc. announced today that the Japanese Ministry of Health, Labour and Welfare granted approval for the new dry eye treatment drug, DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium), on April 16, 2010.

From Santen Pharmaceutical Co., Ltd. 17 Apr 2010

APiX View Detection Kits available for ultra-sensitive chromogenic detection of protein microarrays

Gentel Biosciences, a leader in proteomics discovery tools, today announced the availability of the APiX View Detection Kits for ultra-sensitive chromogenic detection of protein microarrays, including reverse phase protein such as SomaPlex arrays from Protein Biotechnologies.

17 Apr 2010

Sen. Rockefeller casts 'a watchful eye' on insurers' accounting practices

Dow Jones Newswires/ NASDAQ: "A report released Thursday by the chairman of the U.S. Senate Commerce, Science and Transportation Committee cautioned against health insurers using 'creative accounting' to meet new requirements for the amount of premium dollars they spend on patient care." The requirement is that insurers spend 80 percent of the premiums they collect on patient care for small group and individual plans, and 85 percent for large group plans (Brin, 4/15).

17 Apr 2010

RegeneRx Biopharmaceuticals proposes common stock public offering

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering.

17 Apr 2010

MinuteClinic helps patients take control of allergies with treatment services seven days a week

As trees blossom and shed their pollen and grasses and weeds germinate in yards and fields across America, allergy sufferers are retreating indoors with seemingly no relief in sight. MinuteClinic, the walk-in medical clinic inside select CVS/pharmacy stores, can help patients breathe easier and take control of their allergies this spring with treatment services available seven days a week, including weekday evening hours.

16 Apr 2010

Eye News and Research

Latest Eye News and Research

OXiGENE applies for voluntary delisting from SSE, continues to be listed on NASDAQ

Genetic tests that may replace biopsies

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Green tea catechins may protect against glaucoma and other common eye diseases: Scientists

Merck to market and distribute MBL's Td vaccine in the U.S.

IP Advocate founder settles long-standing legal battle with UGARF

A*STAR's BMRC and SIgN award grants for twelve research projects on infectious diseases and immunology

Contrary to previous studies, people with Moebius syndrome lead successful lives

Hearing tests needed for children

Effects of UV radiation may increase chance of developing eye problems later in life

U. S. senators propose retinal scanning may serve as an identity proof

CryoSTAT cold therapy for hemorrhoids

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

Exposure to dust after WTC collapse impairs ability to detect odors and sense irritants

Handheld SD-OCT device helps examine vitreoretinal interface in infants with SBS

Japanese ministry approves DIQUAS Ophthalmic Solution 3% for dry eye treatment

APiX View Detection Kits available for ultra-sensitive chromogenic detection of protein microarrays

Sen. Rockefeller casts 'a watchful eye' on insurers' accounting practices

RegeneRx Biopharmaceuticals proposes common stock public offering

MinuteClinic helps patients take control of allergies with treatment services seven days a week

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Eye News and Research

Latest Eye News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in